Modified Herpes Virus Shows Promise in Phase 3 Melanoma Trial, Improving Survival by 20 Months
核心洞察
A genetically modified herpes virus called T-VEC demonstrated significant efficacy in treating aggressive melanoma (搜索), with 16.3% of patients remaining in remission six months after treatment compared to 2.1% in the control group.
The phase 3 trial involving 436 patients with inoperable melanoma (搜索) showed that T-VEC treatment extended average survival to 41 months versus 21.5 months for the control group receiving immunotherapy.
One in four patients responded positively to the virotherapy treatment, with 10% achieving complete remission and showing no signs of cancer following treatment.
A genetically modified version of the herpes virus has demonstrated remarkable success in treating patients with aggressive melanoma (搜索), marking a significant breakthrough in cancer virotherapy. The phase 3 clinical trial results, published in The Journal of Clinical Oncology, show that the treatment called Talimogene Laherparepvec (T-VEC) helped one in four patients respond positively, with many remaining in remission at least six months after treatment.
Trial Results Show Significant Survival Benefits
The comprehensive study involved 436 patients with inoperable melanoma (搜索) across 64 centers in the UK, US, Canada, and South Africa. Of those treated with T-VEC, 16.3% remained in remission six months after treatment, compared to just 2.1% in the control group who received immunotherapy. Even more encouraging, 10% of T-VEC patients achieved complete remission, showing no signs of cancer following treatment.
The survival data revealed substantial improvements, with T-VEC patients living an average of 41 months compared to 21.5 months for the control group - representing approximately 20 months of extended survival. This represents a significant advancement for patients with advanced melanoma (搜索) who were previously considered too far along to respond to conventional treatments.
Mechanism of Action and Treatment Protocol
The modified herpes virus works through a dual mechanism of action. Researchers removed two genes that prevented the virus from multiplying inside healthy cells, while allowing it to replicate freely within cancerous melanoma (搜索) cells. Additionally, T-VEC has been engineered to produce GM-CSF, a molecule that acts as a signal to the immune system, directing it specifically to tumor sites.
"Meanwhile, T-VEC has also been modified to produce a molecule called GM-CSF, which serves as a red flag waved at the immune system," according to the research findings. "So in addition to the destructive power of the T-VEC cells themselves, the therapy summons the immune system right to where it's needed - the tumour."
The treatment is administered once every two weeks for up to 18 months through direct injection into tumors. While participants experienced flu-like side effects after the first few injections, these were significantly more tolerable than the side effects associated with traditional chemotherapy.
Regulatory Pathway and Market Prospects
Lead researcher Kevin Harrington from the Institute of Cancer Research London (搜索) emphasized the significance of these results: "This is the big promise of this treatment. It's the first time a virotherapy has been shown to be successful in a phase 3 trial."
The findings have already been submitted to drug regulators in Europe and the US. Pharmaceutical company Amgen is seeking approval from the FDA and the European Medicines Agency (搜索), with the European Medicines Agency expected to deliver its verdict later this year. If approved, scientists believe T-VEC could be available to patients by 2016.
Professor Kevin Harrington, who led the trial, stated: "There will have to be discussions about cost effectiveness but we hope to see this agent receive approval in about the next 12 months, making it possible to prescribe it for cancer."
Broader Implications for Cancer Treatment
The success of T-VEC in melanoma (搜索) has opened possibilities for treating other cancer types. Harrington, who has been developing the treatment for over 10 years, tested it across various cancer types and found melanoma responded most positively. The research team plans to continue testing the drug on other forms of cancer through clinical trials.
Professor Paul Workman, chief executive of The Institute of Cancer Research in London, noted: "We may normally think of viruses as the enemies of mankind, but it's their very ability to specifically infect and kill human cells that can make them such promising cancer treatments."
The treatment showed effectiveness even in patients with widespread disease, including those with cancer that had spread to lungs and liver. As Harrington explained, patients "had disease that ranged from dozens to hundreds of deposits of melanoma (搜索) on a limb all the way to patients where cancer had spread to the lungs and liver."
However, specialists emphasize that the treatment may only work for some patients diagnosed with melanoma (搜索), and further research is needed to identify optimal patient selection criteria. According to Cancer Research UK, malignant melanoma is the ninth most common cancer in Europe, with 100,000 new cases of skin cancer (搜索) diagnosed annually in the UK according to The British Skin Foundation.